Sandostatin Lar

Acromegaly, Flushing, Gastroenteritis + 4 more
Treatment
4 FDA approvals
20 Active Studies for Sandostatin Lar

What is Sandostatin Lar

OctreotideThe Generic name of this drug
Treatment SummaryAcromegaly is a disorder caused when the body produces too much growth hormone, leading to increased growth in body tissues and metabolic problems. Octreotide is a medication that helps to reduce growth hormone levels and is used to treat acromegaly and symptoms from various tumors. The drug is usually given as an injection, but on June 26, 2020, the FDA approved the first oral form of octreotide, Mycapssa, for long-term maintenance treatment of acromegaly.
Octreotide Acetateis the brand name
image of different drug pills on a surface
Sandostatin Lar Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Octreotide Acetate
Octreotide
1988
89

Approved as Treatment by the FDA

Octreotide, otherwise known as Octreotide Acetate, is approved by the FDA for 4 uses such as Acromegaly and Flushing .
Acromegaly
Helps manage Acromegaly
Flushing
Gastroenteritis
metastatic Carcinoid Tumors

Effectiveness

How Sandostatin Lar Affects PatientsOctreotide is a drug that works like the natural hormone somatostatin. It is used to treat issues related to tissue growth and insulin regulation in people with acromegaly. It also helps reduce flushing and diarrhea from gastrointestinal tumors. People taking octreotide should be aware that it may reduce gallbladder contractility, bile secretion and the release of thyroid-stimulating hormone (TSH). Additionally, there have been reports of decreased vitamin B12 levels in people taking octreotide, so it is important to monitor vitamin B12 levels in these patients.
How Sandostatin Lar works in the bodyOctreotide is a medication that helps treat excessive growth hormones and other issues related to tumors. It works by binding to specific receptors in the body and causing muscles in blood vessels to tighten. This process then shuts off the production of growth hormones and other hormones involved in the symptoms associated with tumors, like flushing and gastrointestinal problems. Octreotide also reduces the amount of luteinizing hormone and decreases the amount of blood going to certain organs.

When to interrupt dosage

The advocated dosage of Sandostatin Lar is contingent upon the determined circumstance, including Acromegaly, Vasoactive Intestinal Peptide Tumors and metastatic Carcinoid Tumors. The degree of dosage alters, as per the method of delivery (e.g. Injection - Intravenous; Subcutaneous or Capsule, delayed release) mentioned in the following table.
Condition
Dosage
Administration
metastatic Carcinoid Tumors
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Flushing
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Gastroenteritis
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Vasoactive Intestinal Peptide Tumors
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
long-term maintenance therapy
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
octreotide
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Acromegaly
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular

Warnings

Sandostatin Lar Contraindications
Condition
Risk Level
Notes
known hypersensitivity to the drug or any of the ingredients
Do Not Combine
There are 20 known major drug interactions with Sandostatin Lar.
Common Sandostatin Lar Drug Interactions
Drug Name
Risk Level
Description
Dotatate gallium Ga-68
Major
Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Octreotide.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Octreotide.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.
Lutetium Lu 177 dotatate
Major
The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.
Sandostatin Lar Toxicity & Overdose RiskVery few cases of octreotide overdose have been reported, with doses ranging from 2.4 mg/day to 6 mg/day. Side effects of octreotide overdose may include low blood pressure, oxygen deprivation in the brain, irregular heartbeat, heart attack, buildup of lactic acid, pancreatic inflammation, enlarged liver, diarrhea, flushed skin, fatigue, and weakness.
image of a doctor in a lab doing drug, clinical research

Sandostatin Lar Novel Uses: Which Conditions Have a Clinical Trial Featuring Sandostatin Lar?

Currently, 41 active clinical trials are assessing the potential of Sandostatin Lar in providing long-term maintenance therapy for metastatic Carcinoid Tumors, as well as for attenuating flushing.
Condition
Clinical Trials
Trial Phases
Gastroenteritis
26 Actively Recruiting
Phase 1, Phase 2, Phase 4, Phase 3, Not Applicable
Vasoactive Intestinal Peptide Tumors
0 Actively Recruiting
octreotide
0 Actively Recruiting
Acromegaly
6 Actively Recruiting
Phase 3, Phase 2, Not Applicable
long-term maintenance therapy
0 Actively Recruiting
Flushing
2 Actively Recruiting
Not Applicable
metastatic Carcinoid Tumors
2 Actively Recruiting
Phase 2, Early Phase 1

Sandostatin Lar Reviews: What are patients saying about Sandostatin Lar?

5Patient Review
11/20/2013
Sandostatin Lar for Carcinoid Syndrome
I've been on Sandostatin monthly for 14 months, after being diagnosed with a NET tumor of the pancreas with metastasis to the liver last summer. I'm really pleased because there have been no side effects and my blood work shows lowered chromogranin levels - which delights my oncologist. The injection is painful but it's a small price to pay for being able to live a basically normal life at age 60.
5Patient Review
1/13/2010
Sandostatin Lar for Carcinoid Syndrome
My oncologist put me on this drug in October 2009. I have been having monthly injections since, and my blood work looks much better now. My stomach cramps have also improved a lot. The only downside is that it seems like my hair isn't growing as fast, but I don't know if the two are related.
5Patient Review
4/24/2020
Sandostatin Lar for Carcinoid Syndrome
I've been using this medication for over fifteen years with great success. When I started, I had five spots on my liver and now there are only three remaining. The company that makes the drug is also very supportive, checking in with me monthly to see how I'm doing.
5Patient Review
12/5/2016
Sandostatin Lar for Carcinoid Syndrome
I've been taking Sandostatin for about 10 years now. It's helped me shrink a tumor to the point where it could be surgically removed, and I'm still taking it as a preventative measure.
5Patient Review
10/8/2008
Sandostatin Lar for Carcinoid Syndrome
I started this treatment in November 2001 and have been using it every four weeks since. I'm up to a 40mg dose and it has really helped stabilize the tumors in my liver, according to my doctor at MD Anderson Clinic in Houston, Texas.
5Patient Review
9/15/2010
Sandostatin Lar for Increased Size of Hands, Feet and Face
I have acromagly and, post-surgery, I was getting a lot of headaches. This medication completely relieved the pain and has allowed me to live a whole new life.
4.7Patient Review
3/3/2011
Sandostatin Lar for Carcinoid Syndrome
The Sandostatin LAR injections at 30mg have helped to normalize my bowel movements and reduced the frequency of flushing episodes.
4.3Patient Review
12/8/2009
Sandostatin Lar for Pancreatic Tumor causing Excessive Secretion of Insulin
Sandostatin LAR has been highly effective in managing my insulinoma.
4.3Patient Review
11/23/2009
Sandostatin Lar for Carcinoid Syndrome
Since I started getting this treatment every 4 weeks, it's been great. The first month didn't show much of a difference, but now my symptoms only come up occasionally. However, in the last 3-4 weeks, I've experienced sore muscles and unexplained weight loss. I haven't changed my diet or exercise habits, but lost 3# in one week and a total of 5# in the last month. I'll be discussing this with my oncologist soon to see what he thinks. Other than that, the drug has helped me lead a more normal life.
3.7Patient Review
5/26/2009
Sandostatin Lar for Carcinoid Syndrome
This treatment helped me for a while, but now I'm dealing with some serious side effects. My blood sugar is high, my blood pressure is out of control, and I have muscle pain all over my body. If someone so much as touches me, it hurts. I've been told this could be a side effect of the treatment, but I'm really not sure.
3.3Patient Review
1/4/2013
Sandostatin Lar for Carcinoid Syndrome
I receive an IM injection of 30 mg every four weeks. However, this has not been effective in slowing the growth of carcinoid tumors on my liver after two years. I've had to have SIRT procedures done to remove the tumors from my liver. My oncologist says I should continue taking the injections, though.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sandostatin lar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Sandostatin LAR?

"The most common symptoms of the flu are:

  • back pain
  • fatigue
  • headache
  • abdominal pain
  • nausea
  • dizziness"
Answered by AI

What is Sandostatin LAR used for?

"This action medication is a slow-acting form of octreotide. Octreotide is used to treat patients with serious diarrhea that is watery, and also sudden reddening in the face and neck area. These types of tumors are found mostly in the intestines and pancreas."

Answered by AI

Is Sandostatin LAR chemotherapy?

"Sandostatin is not a chemotherapy drug. Rather, it is a man-made hormone with similar effects to somatostatin, a hormone that is produced naturally in our bodies by the hypothalamus and other tissues such as the pancreas and the gastrointestinal tract."

Answered by AI

How is Sandostatin LAR given?

"Sandostatin LAR is a long-acting version of the drug octreotide, which is used to treat hormone imbalances. Octreotide is similar to the hormone somatostatin, and is more potent than somatostatin in its ability to inhibit growth hormone, glucagon, and insulin."

Answered by AI

Clinical Trials for Sandostatin Lar

Have you considered Sandostatin Lar clinical trials? We made a collection of clinical trials featuring Sandostatin Lar, we think they might fit your search criteria.
Have you considered Sandostatin Lar clinical trials? We made a collection of clinical trials featuring Sandostatin Lar, we think they might fit your search criteria.
Have you considered Sandostatin Lar clinical trials? We made a collection of clinical trials featuring Sandostatin Lar, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top